CONTENTS:
• The design and analysis of multisite effectiveness trials: a decade of progress in the national drug abuse clinical trials network. Nunes E.V., p. 269-272.
• Ten take home lessons from the first 10 years of the CTN and 10 recommendations for the future. Carroll K.M., Ball S.A., Jackson R., Martino S., Petry N.M., Stitzer M.L., et al., p. 275-282.
• NIDA's clinical trials network: an opportunity for HIV research in community substance abuse treatment programs. Tross S., Campbell A.N.C., Calsyn D.A., Metsch L.R., Sorensen J.L., Shoptaw S., et al., p. 283-293.
• Is monogamy or committed relationship status a marker for low sexual risk among men in substance abuse treatment? Clinical and methodological considerations. Calsyn D.A., Campbell A.N., Tross S., Hatch-Maillette M.A., p. 294-300.
• Gender research in the National Institute on Drug Abuse National Treatment Clinical Trials Network: A summary of findings. Greenfield S.F., Rosa C., Putnins S.I., Green C.A., Brooks A.J., Calsyn D.A., et al., p. 301-312.
• Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial. Back S.E., Payne R.L., Wahlquist A.H., Carter R.E., Stroud Z., Haynes L., et al., p. 313-323.
• Conducting research with racial/ethnic minorities: Methodological lessons from the NIDA Clinical Trials Network. Burlew A.K., Weekes J.C., Montgomery L., Feaster D.J., Robbins M.S., Rosa C.L., et al., p. 324-332.
• Research partnerships between academic institutions and American Indian and Alaska native tribes and organizations: Effective strategies and lessons learned in a multisite CTN study. Thomas L.R., Rosa C., Forcehimes A., Donovan D.M., p. 333-338.
• Determining the primary endpoint for a stimulant abuse trial: Lessons learned from STRIDE (CTN 0037). Trivedi M.H., Greer T.L., Potter J.S., Grannemann B.D., Nunes E.V., Rethorst C., et al., p. 339-349.
• Power of automated algorithms for combining time-line follow-back and urine drug screening test results in stimulant-abuse clinical trials. Oden N.L., VanVeldhuisen P.C., Wakim P.G., Trivedi M.H., Somoza E., Lewis D., p. 350-357.
• Assessing drug use during follow-up: direct comparison of candidate outcome definitions in pooled analyses of addiction treatment studies. Korte J.E., Magruder K.M., Chiuzan C.C., Logan S.L., Killeen T., Bandyopadhyay D., et al., p. 358-366.
• Zero-inflated and hurdle models of count data with extra zeros: Examples from an HIV-risk reduction intervention trial. Hu M.C., Pavlicova M., Nunes E.V., p. 367-375.
• Some considerations for excess zeroes in substance abuse research. Bandyopadhyay D., DeSantis S.M., Korte J.E., Brady K.T., p. 376-382.
• Modeling site effects in the design and analysis of multi-site trials. Feaster D.J., Mikulich-Gilbertson S., Brincks A.M., p. 383-391.
• An exploration of site effects in a multisite trial of OROS-Methylphenidate for smokers with attention deficit/hyperactivity disorder. Covey L.S., Hu M.C., Green C.A., Brigham G., Hurt R.D., Adler L., et al., p. 392-399.
• Site selection in community-based clinical trials for substance use disorders: strategies for effective site selection. Potter J.S., Donovan D.M., Weiss R.D., Gardin J., Lindblad R., Wakim P., et al., p. 400-407.
• How practice and science are balanced and blended in the NIDA Clinical Trials Network: The bidirectional process in the development of the STAGE-12 protocol as an example. Donovan D.M., Daley D.C., Brigham G.S., Hodgkins C.C., Perl H.I., Floyd A.S., p. 408-416.
• Design of NIDA CTN Protocol 0047: Screening, motivational assessment, referral, and treatment in emergency departments (SMART-ED). Bogenschutz M.P., Donovan D.M., Adinoff B., Crandall C., Forcehimes A.A., Lindblad R., et al., p. 417-425.
• Relation of study design to recruitment and retention in CTN trials. Wakim P.G., Rosa C., Kothari P., Michel M.E., p. 426-433.
• Standardized patient walkthroughs in the National Drug Abuse Treatment Clinical Trials Network: Common challenges to protocol implementation. Fussell H.E., Kunkel L.E., McCarty D., Lewy C.S., p. 434-439.
• Strategies for safety reporting in substance abuse trials. Lindblad R., Campanella M., Styers D., Kothari P., Sparenborg S., Rosa C., p. 440-445.
• Baseline matters: The importance of covariation for baseline severity in the analysis of clinical trials. Nunes E.V., Pavlicova M., Hu M.C., Campbell A.N., Miele G., Hien D., et al., p. 446-452.
• Participant characteristics and buprenorphine dose. Hillhouse M., Canamar C.P., Doraimani G., Thomas C., Hasson A., Ling W., p. 453-459.
• Rates and influences of alcohol use disorder comorbidity among primary stimulant misusing treatment-seekers: Meta-analytic findings across eight NIDA CTN trials. Hartzler B., Donovan D.M., Huang Z., p. 460-471.
• Smoking cessation treatment among patients in community-based substance abuse rehabilitation programs: exploring predictors of outcome as clues toward treatment improvement. Reid M.S., Jiang H.P., Fallon B., Sonne S., Rinaldi P., Turrigiano E., et al., p. 472-478.